SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
Delayed Swiss Exchange  -  03:48 2022-08-17 am EDT
0.7500 CHF   -0.66%
06/30Santhera's Shareholders Approve all Board Proposals at Today's Annual General Meeting
AQ
06/30Santhera's Shareholders Approve all Board Proposals at Today's Annual General Meeting
GL
06/30Santhera Pharmaceuticals Holding AG Announces Board Changes
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
08/11/2022 08/12/2022 08/15/2022 08/16/2022 08/17/2022 Date
0.801(c) 0.8(c) 0.785(c) 0.755(c) 0.75 Last
219 650 121 268 131 344 108 487 15 779 Volume
-4.42% -0.12% -1.88% -3.82% -0.66% Change
More quotes
Estimated financial data (e)
Sales 2022 8,80 M 9,26 M 9,26 M
Net income 2022 -43,0 M -45,2 M -45,2 M
Net Debt 2022 - - -
P/E ratio 2022 -0,97x
Yield 2022 -
Sales 2023 49,4 M 52,0 M 52,0 M
Net income 2023 -5,00 M -5,26 M -5,26 M
Net Debt 2023 - - -
P/E ratio 2023 -9,44x
Yield 2023 -
Capitalization 39,2 M 41,3 M 41,3 M
Capi. / Sales 2022 4,46x
Capi. / Sales 2023 0,79x
Nbr of Employees 39
Free-Float 81,5%
More Financials
Company
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of Santhera Pharmaceuticals Holding AG
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about SANTHERA PHARMACEUTICALS HOLDING AG
06/30Santhera's Shareholders Approve all Board Proposals at Today's Annual General Meeting
AQ
06/30Santhera's Shareholders Approve all Board Proposals at Today's Annual General Meeting
GL
06/30Santhera Pharmaceuticals Holding AG Announces Board Changes
CI
06/30SANTHERA PHARMACEUTICALS : Shareholders Approve all Board Proposals at Today's Annual Gene..
PU
06/29Santhera Faces Delay in US FDA New Drug Submission For Duchenne Muscular Dystrophy Drug
MT
06/29Santhera Updates on Ongoing NDA Submission for Vamorolone
GL
06/29Santhera Updates on Ongoing NDA Submission for Vamorolone
DJ
06/29Santhera Pharmaceuticals Holding AG Updates on Ongoing NDA Submission for Vamorolone
CI
06/27Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board
GL
06/27Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board
DJ
06/27Santhera Pharmaceuticals Holding AG Announces that Elmar Schnee will not stand for re-e..
CI
06/10TRANSCRIPT : Santhera Pharmaceuticals Holding AG, 2021 Earnings Call, Jun 10, 2022
CI
06/10SANTHERA PHARMACEUTICALS : 2021 Santhera Annual Report
PU
06/10Santhera Reports 2021 Annual Results
GL
06/10Santhera Reports 2021 Annual Results
AQ
More news
News in other languages on SANTHERA PHARMACEUTICALS HOLDING AG
06/30Santhera's Aktionäre stimmen an heutiger Generalversammlung allen Anträgen des Verwaltu..
06/30Santhera's Aktionäre stimmen an heutiger Generalversammlung allen Anträgen des Verwaltu..
06/30Santhera Pharmaceuticals Holding AG annonce des changements au sein de son conseil d'ad..
06/29SANTHERA : l'homologation du vamorolone aux USA prend du retard
06/29Santhera erwartet Verzögerung bei US-Zulassungsantrag für Vamorolone
More news
Chart SANTHERA PHARMACEUTICALS HOLDING AG
Duration : Period :
Santhera Pharmaceuticals Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANTHERA PHARMACEUTICALS HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,76 CHF
Average target price 5,50 CHF
Spread / Average Target 628%
EPS Revisions
Managers and Directors
Dario Eklund Chief Executive Officer
Andrew P. Smith Chief Financial Officer
Thomas Meier Chairman
Shabir Hasham Chief Medical Officer
Philipp Gutzwiller Independent Director
Sector and Competitors